North America Plasma Fractionation Market By Product (Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX), By Sector (Private Sector and Public Sector), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

The North America Plasma Fractionation Market is expected to witness market growth of 8.3% CAGR during the forecast period (2021-2027).

Fractionation refers to a process performed in order to separate a particular quantity of a mixture. Moreover, plasma refers to a fluid part of blood, which is fractionated to extract various plasma derivatives like albumin and immunoglobulins. These extracted plasma products show therapeutic properties and are used to treat several blood plasma-related diseases. For example, coagulation factor VIII refers to a plasma derivative that is utilized for treating and prophylaxis of hemophilia. Moreover, it is also utilized in order to stop extreme blood loss during surgical procedures. Likewise, immunoglobulins are used in treating primary and secondary immune deficiencies.

Plasma-derived immunoglobulins are being highly utilized in various clinical indications like autoimmune and inflammatory diseases. The plasma fractionation market is putting massive investment in therapies like Plasmin, Ceruloplasmin, and IgA. Additionally, thriving investments in innovation and technological developments in effective and cost-efficient techniques for fractioning proteins will provide momentum to the plasma fractionation market.

Though, disruption in raw material supply was neutralized by a decline in demand for plasma derivatives during the onset of country-wise lockdowns, as elective surgical methods were delayed and accessibility of treatment for other medical conditions was also hindered. Additionally, the overall plasma supply in different nations is the same as before; though, some parts of the world may witness shortages. Therefore, the COVID-19 pandemic brought an adverse impact on the growth of the overall plasma fractionation market.

The US market dominated the North America Coagulation factor VIII Market by Country in 2020, thereby, achieving a market value of $787.4 Million by 2027. The Canada market is experiencing a CAGR of 12.3% during (2021 - 2027). Additionally, The Mexico market is expected to witness a CAGR of 11.4% during (2021 - 2027).

Based on Product, the market is segmented into Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX. Based on Sector, the market is segmented into Private Sector and Public Sector. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Emergent BioSolutions, Inc., CSL Limited, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, LFB S.A, Biotest AG (Tiancheng International Investment Limited), Sanquin Blood Supply Foundation, and Bio Products Laboratory Limited.

Scope of the Study

Market Segments covered in the Report:

By Product

• Immunoglobulins
• Albumin
• Coagulation factor VIII
• Coagulation factor IX

By Sector

• Private Sector
• Public Sector

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Emergent BioSolutions, Inc.
• CSL Limited
• Grifols S.A.
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Kedrion S.p.A
• LFB S.A
• Biotest AG (Tiancheng International Investment Limited)
• Sanquin Blood Supply Foundation
• Bio Products Laboratory Limited

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free